Related Experiment Videos
The Frankfurt experience in restenosis after coronary angioplasty
Insights
High-dose aspirin therapy is crucial for reducing restenosis after percutaneous transluminal coronary angioplasty (PTCA). Continuing 1.5 g of acetylsalicylic acid post-procedure significantly lowers restenosis rates compared to reduced or discontinued doses.
Area of Science:
- Cardiology
- Interventional Cardiology
Background:
- Percutaneous transluminal coronary angioplasty (PTCA) is a common procedure for treating coronary artery disease.
- Restenosis, the re-narrowing of an artery after PTCA, remains a significant clinical challenge, affecting treatment efficacy.
- Optimizing medical therapy, particularly antiplatelet agents, is key to improving long-term outcomes post-PTCA.
Purpose of the Study:
- To evaluate the impact of acetylsalicylic acid dosage on restenosis rates following PTCA.
- To determine the necessity of high-dose acetylsalicylic acid therapy for preventing restenosis in patients undergoing PTCA.
Main Methods:
- Retrospective analysis of angiographic follow-up data from 356 patients who underwent PTCA.
- Comparison of restenosis rates between patients receiving standard high-dose aspirin (1.5 g daily) and those with reduced or discontinued aspirin therapy.
- Definition of restenosis as >30% increase in stenosis or loss of ≥50% of initial luminal gain.
Main Results:
- A high reangiography rate of 94% was observed, with an overall first PTCA recurrence rate of 15%.
- Patients receiving reduced or discontinued aspirin therapy showed significantly higher restenosis rates (38%) compared to those on high-dose aspirin (17%).
- A reduced dose of aspirin was associated with a 32% restenosis rate.
Conclusions:
- High-dose acetylsalicylic acid therapy, administered before, during, and for 4-6 months after PTCA, is essential for achieving low restenosis rates.
- Maintaining a consistent 1.5 g daily dose of aspirin appears necessary to minimize the risk of restenosis after coronary angioplasty.
- These findings underscore the importance of adherence to high-dose aspirin regimens in post-PTCA management to prevent arterial re-narrowing.
Abstract:
Three hundred and thirty-three of 356 patients underwent angiographic follow-up from 1 to 18 months (mean 5.6 months) after percutaneous transluminal coronary angioplasty (PTCA). This is a reangiography rate of 94%. Recurrence rate after the first PTCA was 15% (n = 289). Restenosis rate was defined as an increase from immediate post-PTCA stenosis of more than 30%, or the loss of at least half of the initial gain in luminal diameter. Patients who needed a second angioplasty due to restenosis (n = 30) had a restenosis rate of 33%. Patients with angioplasty in the aortocoronary bypass (n = 14) had a restenosis rate of 45%. All patients were treated before, during and at least 4 to 6 months after the procedure with 60 to 100 mg of isosorbide dinitrate daily plus 160 to 360 mg of verapamil or 100 to 150 mg of gallopamil and 1.5 g of acetylsalicylic acid. In a second retrospective study 111 of 399 patients had the acetylsalicylic acid therapy discontinued or decreased. Forty-two of them developed restenosis (38%), whereas only 49 of 288 patients who continued to receive 1.5 g aspirin developed restenosis (17%). The restenosis rate was 32% in those who received the reduced dose of aspirin. Thus, a large dose of acetylsalicylic acid given before, during and 4 to 6 months after the procedure seems to be necessary to achieve a low rate of restenosis after PTCA.